• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2 型糖尿病患者肝细胞癌预测的风险评分系统:台湾糖尿病研究。

Risk score system for the prediction of hepatocellular carcinoma in patients with type 2 diabetes: Taiwan Diabetes Study.

机构信息

Department of Public Health, College of Public Health, China Medical University, Taichung, Taiwan; Department of Healthcare Administration, College of Medical and Health Science, Asia University, Taichung, Taiwan.

School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan; Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.

出版信息

Semin Oncol. 2018 Oct;45(5-6):264-274. doi: 10.1053/j.seminoncol.2018.07.006. Epub 2018 Oct 17.

DOI:10.1053/j.seminoncol.2018.07.006
PMID:30342872
Abstract

This study aims to develop a risk score system for hepatocellular carcinoma (HCC) in patients with type 2 diabetes using the Taiwan National Diabetes Care Management Program database. This retrospective cohort study included 31,723 Chinese patients who had type 2 diabetes, aged 30-84 years. Participants were randomly grouped into derivation and validation sets in 2:1 ratio. Cox proportional hazard regression models were used to identify the risk factors of HCC in the derivation set. Discrimination ability of the model was assessed by means of a receiver operating characteristic curve and performance was expressed as the c statistic, assessed internally on validation data sets. The average follow-up was 8.33 years with 748 HCC incident cases in the derivation set. The final HCC risk score system included age (-2 to 8 points), gender (0-2 points), smoking (0-2 points), variation in hemoglobin A1c (0-1 point), serum glutamic-pyruvic transaminase (0-6 points), liver cirrhosis (9 points), hepatitis B (4 points), hepatitis C (3 points), antidiabetes medications (0-3 points), and antihyperlipidemia medications and total/high-density lipoprotein cholesterol ratio (-4 to 2 points). The HCC risk score was the sum of these individual scores (range -6 to 40). The area under the receiver operating characteristic curve for 3-, 5-, and 10-year HCC risks was 0.81, 0.80, and 0.77 for the derivation set, respectively. This HCC risk score system has good prediction accuracy and discriminatory ability, and serves a simple tool for HCC risk prediction.

摘要

本研究旨在利用台湾国家糖尿病照护管理计划数据库,为 2 型糖尿病患者开发肝细胞癌(HCC)风险评分系统。这项回顾性队列研究纳入了 31723 名年龄在 30-84 岁的中国 2 型糖尿病患者。参与者以 2:1 的比例随机分为推导组和验证组。在推导组中,使用 Cox 比例风险回归模型确定 HCC 的风险因素。通过接受者操作特征曲线评估模型的判别能力,并在验证数据集上进行内部评估,以 c 统计量表示性能。平均随访时间为 8.33 年,推导组中有 748 例 HCC 发病病例。最终的 HCC 风险评分系统包括年龄(-2 至 8 分)、性别(0-2 分)、吸烟(0-2 分)、糖化血红蛋白变异(0-1 分)、血清谷氨酸丙酮酸转氨酶(0-6 分)、肝硬化(9 分)、乙型肝炎(4 分)、丙型肝炎(3 分)、抗糖尿病药物(0-3 分)以及降血脂药物和总/高密度脂蛋白胆固醇比值(-4 至 2 分)。HCC 风险评分是这些个体评分的总和(范围-6 至 40)。推导组中,3 年、5 年和 10 年 HCC 风险的受试者工作特征曲线下面积分别为 0.81、0.80 和 0.77。该 HCC 风险评分系统具有良好的预测准确性和判别能力,是一种用于 HCC 风险预测的简单工具。

相似文献

1
Risk score system for the prediction of hepatocellular carcinoma in patients with type 2 diabetes: Taiwan Diabetes Study.2 型糖尿病患者肝细胞癌预测的风险评分系统:台湾糖尿病研究。
Semin Oncol. 2018 Oct;45(5-6):264-274. doi: 10.1053/j.seminoncol.2018.07.006. Epub 2018 Oct 17.
2
Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles.慢性乙型肝炎患者长期肝硬化和肝细胞癌风险的预测模型:整合宿主和病毒特征的风险评分。
Hepatology. 2013 Aug;58(2):546-54. doi: 10.1002/hep.26385.
3
Predictors of Increased Risk of Hepatocellular Carcinoma in Patients with Type 2 Diabetes.2型糖尿病患者肝细胞癌风险增加的预测因素
PLoS One. 2016 Jun 30;11(6):e0158066. doi: 10.1371/journal.pone.0158066. eCollection 2016.
4
Hyperglycemia and chronic liver diseases on risk of hepatocellular carcinoma in Chinese patients with type 2 diabetes--National cohort of Taiwan Diabetes Study.中国2型糖尿病患者的高血糖与慢性肝病对肝细胞癌风险的影响——台湾糖尿病研究全国队列
Int J Cancer. 2015 Jun 1;136(11):2668-79. doi: 10.1002/ijc.29321. Epub 2014 Dec 1.
5
Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B.接受口服抗病毒治疗的初治慢性乙型肝炎患者发生肝细胞癌的风险评分模型
Clin Mol Hepatol. 2017 Jun;23(2):170-178. doi: 10.3350/cmh.2016.0086. Epub 2017 May 16.
6
Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score.REACH-B 研究:慢性乙型肝炎患者肝细胞癌风险预测评分的建立与验证
Lancet Oncol. 2011 Jun;12(6):568-74. doi: 10.1016/S1470-2045(11)70077-8. Epub 2011 Apr 14.
7
PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy.PAGE-B 预测了慢性乙型肝炎患者在接受 5 年抗病毒治疗后发生肝细胞癌的风险。
J Hepatol. 2016 Apr;64(4):800-6. doi: 10.1016/j.jhep.2015.11.035. Epub 2015 Dec 8.
8
Hepatocellular carcinoma risk prediction model for the general population: the predictive power of transaminases.人群肝细胞癌风险预测模型:转氨酶的预测能力。
J Natl Cancer Inst. 2012 Oct 17;104(20):1599-611. doi: 10.1093/jnci/djs372.
9
Development of a prediction model for 10-year risk of hepatocellular carcinoma in middle-aged Japanese: the Japan Public Health Center-based Prospective Study Cohort II.开发一种用于预测中年日本人 10 年内肝细胞癌风险的模型:日本基于公共卫生中心的前瞻性研究队列 II。
Prev Med. 2012 Aug;55(2):137-43. doi: 10.1016/j.ypmed.2012.05.017. Epub 2012 Jun 4.
10
Risk score prediction model for dementia in patients with type 2 diabetes.2 型糖尿病患者痴呆风险评分预测模型。
Eur J Neurol. 2018 Jul;25(7):976-983. doi: 10.1111/ene.13642. Epub 2018 May 2.

引用本文的文献

1
Comparison of models to predict incident chronic liver disease: a systematic review and external validation in Chinese adults.预测新发慢性肝病模型的比较:一项针对中国成年人的系统评价与外部验证
BMC Med. 2024 Dec 31;22(1):601. doi: 10.1186/s12916-024-03754-9.
2
Scoring System for Predicting the Risk of Liver Cancer among Diabetes Patients: A Random Survival Forest-Guided Approach.糖尿病患者肝癌风险预测评分系统:一种随机生存森林引导的方法。
Cancers (Basel). 2024 Jun 24;16(13):2310. doi: 10.3390/cancers16132310.
3
A prospective study on the prevalence of at-risk MASH in patients with type 2 diabetes mellitus in the United States.
美国 2 型糖尿病患者高危 MASH 患病率的前瞻性研究。
Aliment Pharmacol Ther. 2024 Jun;59(12):1571-1578. doi: 10.1111/apt.17997. Epub 2024 Apr 8.
4
Development and prognosis of hepatocellular carcinoma in patients with diabetes.糖尿病患者肝细胞癌的发生和预后。
Clin Mol Hepatol. 2023 Jan;29(1):51-64. doi: 10.3350/cmh.2022.0095. Epub 2022 Jul 29.
5
Risk factors of hepatocellular carcinoma in type 2 diabetes patients: A two-centre study in a developing country.2 型糖尿病患者肝细胞癌的风险因素:发展中国家的一项两中心研究。
PLoS One. 2021 Dec 9;16(12):e0260675. doi: 10.1371/journal.pone.0260675. eCollection 2021.
6
Surveillance for hepatocellular carcinoma in chronic viral hepatitis: Is it time to personalize it?慢性病毒性肝炎肝细胞癌的监测:是否到了个体化的时代?
World J Gastroenterol. 2021 Sep 7;27(33):5536-5554. doi: 10.3748/wjg.v27.i33.5536.
7
Role of Liver-Mediated Tolerance in Nanoparticle-Based Tumor Therapy.肝脏介导的耐受在基于纳米颗粒的肿瘤治疗中的作用。
Cells. 2020 Aug 28;9(9):1985. doi: 10.3390/cells9091985.
8
Comorbidity Risk Score in Association with Cancer Incidence: Results from a Cancer Screenee Cohort.合并症风险评分与癌症发病率的关系:来自癌症筛查队列的结果
Cancers (Basel). 2020 Jul 8;12(7):1834. doi: 10.3390/cancers12071834.
9
How to improve HCC surveillance outcomes.如何改善肝癌监测结果。
JHEP Rep. 2019 Nov 5;1(6):460-467. doi: 10.1016/j.jhepr.2019.10.007. eCollection 2019 Dec.
10
Poorly Differentiated Hepatocellular Carcinoma in a Low-risk Patient with an Otherwise Normal Liver.低风险患者肝脏其他方面正常情况下的低分化肝细胞癌
Intern Med. 2020 Feb 1;59(3):365-372. doi: 10.2169/internalmedicine.3577-19. Epub 2019 Oct 17.